Bull case
Cytokinetics is attractive because aficamten has delivered statistically significant and clinically meaningful benefits in nHCM, including improved KCCQ-CSS, pVO2, NYHA class response, NT-proBNP, and broad consistency across prespecified subgroups, which supports a differentiated mechanism and meaningful unmet-need opportunity. Its commercial outlook is also strengthening, with MYQORZO launching strongly in the U.S. and Europe, more than 2,500 REMS-certified HCPs, over 700 prescribers, over 80% of patients on paid therapy, and 2Q26 product sales of about $25MM alongside total revenues of $28.6M. The outlook is further reinforced by a $1.7B balance sheet, advancing regulatory milestones including the November 14, 2026 PDUFA date and a planned 4Q26 sNDA filing, plus a pipeline that could broaden Cytokinetics into a multi-asset cardiology platform.